



Universiteit
Leiden
The Netherlands

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

Verheijden, R.J.; May, A.M.; Blank, C.U.; Veldt, A.A.M. van der; Boers-Sonderen, M.J.; Aarts, M.J.B.; ... ; Suijkerbuijk, K.P.M.

Citation

Verheijden, R. J., May, A. M., Blank, C. U., Veldt, A. A. M. van der, Boers-Sonderen, M. J., Aarts, M. J. B., ... Suijkerbuijk, K. P. M. (2020). Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. *Esmo Open*, 5(6). doi:10.1136/esmoopen-2020-000945

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3184765>

Note: To cite this publication please use the final published version (if applicable).

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease



Rik J Verheijden ¹, Anne M May,² Christian U Blank ³, Astrid A M van der Veldt,⁴ Marye J Boers-Sonderen,⁵ Maureen J B Aarts,⁶ Franchette W P J van den Berkmortel,⁷ Alfonsus J M van den Eertwegh,⁸ Jan Willem B de Groot,⁹ Jacobus J M van der Hoeven,⁵ Geke A P Hospers,¹⁰ Djura Piersma,¹¹ Rozemarijn S van Rijn,¹² Albert J ten Tije,¹³ Gerard Vreugdenhil,¹⁴ Michiel C T van Zeijl,^{15,16} Michel W J M Wouters,^{16,17} John B A G Haanen ¹⁸, Ellen Kapiteijn,¹⁵ Karijn P M Suijkerbuijk¹

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/esmoopen-2020-000945>).

To cite: Verheijden RJ, May AM, Blank CU, *et al.* Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. *ESMO Open* 2020;5:e000945. doi:10.1136/esmoopen-2020-000945

Received 24 July 2020
Revised 1 October 2020
Accepted 19 October 2020

Published online
16 November 2020

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

For numbered affiliations see end of article.

Correspondence to
Karijn P M Suijkerbuijk;
K.Suijkerbuijk@umcutrecht.nl

ABSTRACT

Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimic immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tumour-related factors associated with an increased risk of irAEs have been identified until now.

Methods Risk ratios of severe (grade ≥ 3) irAEs for age, sex, WHO performance status, number of comorbidities, stage of disease, number of metastases and serum lactate dehydrogenases (LDH) were estimated using data from anti-PD1-treated patients with advanced melanoma in the prospective nationwide Dutch Melanoma Treatment Registry. **Results** 111 (11%) out of 819 anti-programmed cell death 1 treated patients experienced severe irAEs. Patients with non-lung visceral metastases (stage IV M1c or higher) less often experienced severe irAEs (11%) compared with patients with only lung and/or lymph node/soft tissue involvement (stage IV M1b or lower; 19%; adjusted risk ratio (RR_{adj}) 0.63; 95% CI 0.41 to 0.94). Patients with LDH of more than two times upper limit of normal had a non-significantly lower risk of developing severe irAEs than those with normal LDH (RR_{adj} 0.65; 95% CI 0.20 to 2.13). None of the other variables were associated with severe irAEs.

Conclusion In patients with melanoma, more advanced disease is associated with a lower rate of severe irAEs. No association with sex was found.

INTRODUCTION

Through the blockage of programmed cell-death 1 (PD-1), the immune checkpoint inhibitors (ICIs) nivolumab and pembrolizumab reinvigorate tumour-specific T cells, potentially resulting in long-lasting antitumour response and increased overall survival in several types of malignancies, such as advanced melanoma, non-small cell lung cancer and renal cell carcinoma.^{1,2} On the other hand, checkpoint inhibition can cause immune-related adverse events (irAEs), ranging from mild to severe, which can be irreversible and in some cases fatal.³

Key questions

What is already known about this subject?

► Immune checkpoint inhibitor can cause severe and sometimes fatal immune-related adverse events (irAEs). No demographic or tumour-related factors associated with an increased risk of irAEs have been identified until now.

What does this study add?

► This study demonstrates that more advanced disease is associated with a significant decreased risk of severe irAEs in patients with melanoma.

How might this impact on clinical practice?

► By improving irAE risk prediction in individual patients, these data contribute to better informed shared decision-making.

As ICIs are now used as adjuvant treatment, trying to improve cure rates for stage III and resected stage IV melanoma and non-squamous cell lung cancer, it is becoming more and more important to identify patients who are at increased risk for severe ICI toxicity.

irAEs mimic autoimmune disease that are known to have a female predominance.⁴ In line with that, women might be more prone to develop irAEs during checkpoint inhibition.^{5,6} In addition, the high toxicity rates in early (neo)adjuvant studies have led to the hypothesis that irAEs occur more frequently in patients with lower tumour load.⁷

Studies so far investigating determinants of anti-PD(L)1 toxicity were of limited sample size with a median of 78 patients at risk (IQR 50–128).^{8–21} Here we analysed whether demographic and disease-specific patient characteristics present at start of treatment were associated with an increased risk of severe irAEs using a large dataset from our nationwide melanoma treatment registry.

METHODS

Patients

The Dutch Melanoma Treatment Registry (DMTR) prospectively registers demographic and clinical data from all unresectable patients with stage III and IV melanoma in the Netherlands since 2012.²² In this report, we included all patients who received either nivolumab or pembrolizumab monotherapy from 1 July 2012 until 31 December 2017 as first ICI. Patients who were previously treated with ipilimumab or combined ipilimumab plus nivolumab were not included in this report to exclude the possibility of overlapping toxicity. Patients who were censored due to data cut-off within 3 months after treatment initiation were excluded, as they had a substantial risk of getting an irAE after censoring.²³ Toxicities were graded according to the Common Terminology Criteria of Adverse Events V.4.03. In the DMTR, only severe irAEs are registered (ie, \geq grade 3). In compliance with Dutch regulations, the DMTR was approved by the medical ethical committee and was not subject to the Medical Research Involving Human Subjects Act.

Statistical analyses

Variables age, sex, WHO performance status (0 vs 1 vs \geq 2), number of comorbidities, stage of disease (American Joint Committee on Cancer V.8; unresectable stage III/stage IV M1a/M1b vs stage IV M1c/M1d), number of metastatic sites ($<$ 5 vs \geq 5) and serum lactate dehydrogenase (LDH; \leq upper limit of normal (ULN; 250 U/L) vs 1–2 \times ULN vs $>$ 2 \times ULN) at start of treatment were tested for correlation with severe irAEs. Furthermore, in a subgroup of patients who were solely in stage M1c/M1d, the correlation of symptomatic brain metastases with severe irAEs was tested. At first, since irAE is a frequently occurring outcome,^{24 25} unadjusted risk ratio (RR) of severe irAEs including 95% CI was calculated using Poisson regression. Then, multivariable Poisson regression analysis was used to calculate adjusted RR for each variable, with all other variables and follow-up time (time from start of treatment until death/censoring) as covariate. Both univariable and multivariable analyses were performed in treatment-naïve patients and in patients receiving first ICI treatment irrespective of line of systemic treatment (including first line) with additional adjustment for line of therapy in the multivariable analyses. Significant results were then verified in only patients who were alive 3 months after treatment initiation to account for time dependency of severe irAEs. For multivariable analyses, missing variable data were imputed using the mice package in R.²⁶ For each analysis, a number of imputed datasets were created, corresponding to the percentage of patients in which at least one variable was missing (eg, 16 for first-line anti-PD1 and 18 for all line anti-PD1 therapy).²⁷ Mann-Whitney U test was used to test for differences in treatment duration, as this was not normally distributed. All analyses were done using two-sided tests. P values $<$ 0.05 were considered significant. R V.3.5.1 was used including dplyr, mice, stats and survival packages.

RESULTS

In total, 927 patients receiving nivolumab (n=283) or pembrolizumab (n=644) in any line between 2012 and 2017 were registered. Sixty-two patients were excluded because of missing toxicity status. Additionally, 46 patients who were censored due to data cut-off within 3 months after start of therapy were excluded; the remaining 819 patients were included in this study. Median follow-up after start of treatment was 11 months (IQR 5–17). Patients received a median of seven cycles of anti-PD1 therapy (IQR 3–15). A total of 557 patients were treated in first line, 208 were treated in second line, 39 in third line and 15 in later lines (table 1).

Among patients treated with anti-PD1 in any line, 111 (14%) suffered severe (ie, grade \geq 3) irAEs. These included colitis (n=23; 2.8%), hepatitis (n=14; 1.7%), dermatitis (n=13; 1.6%), pneumonitis (n=10; 1.2%), endocrine toxicities (n=9; 1.1%), including thyroiditis (n=5; 0.6%) and other toxicities (n=56; 6.8%). Four patients died because of treatment related grade 5 toxicity. Median duration on treatment was 139 days (IQR=58–313) for patients with severe irAEs and 105 days (42–252) for patients without, which was not significantly different (p=0.14). Data on treatment duration were incomplete in 8% and 16% of patients with and without severe irAEs.

Patients with stage IV M1c or higher significantly less often experienced severe irAEs: 63 (11%)/565, compared with 45 (19%)/232 with stage IV M1b or lower disease (RR 0.57; 95% CI 0.39 to 0.85; RR_{adj} 0.63; 95% CI 0.41 to 0.94). Of note, when including solely those 706 patients who were alive 3 months after treatment initiation, the association remained significant (RR_{adj} 0.65; 95% CI 0.42 to 0.99). Patients with an LDH \geq 2 \times ULN had a non-significant decreased risk of severe irAEs compared with patients with normal LDH (RR_{adj} 0.65; 95% CI 0.20 to 2.13). Neither in univariable nor multivariable Poisson regression analysis, any of the other tested variables age, sex, WHO performance status, number of comorbidities, stage of disease, number of metastases and line of therapy were significantly associated with severe irAEs (table 2).

When analysing first-line anti-PD1-treated patients only, 78 (14%) of the first-line anti-PD1-treated patients experienced severe irAEs. A total of 44 (12%)/359 patients with stage IV M1c or higher had severe irAEs compared with 33 (18%)/186 patients with stage M1b or lower, resulting in a unadjusted RR for severe irAEs of 0.69 (95% CI 0.44 to 1.09) and an adjusted risk ratio (RR_{adj}) of 0.73 (95% CI 0.45 to 1.18), which was not significantly different. Again, patients with LDH $>$ 2 \times ULN had a non-significantly lower risk of developing severe irAEs compared with those with normal LDH (RR_{adj} 0.73; 95% CI 0.17 to 3.00). None of the other variables were significantly associated with severe irAEs in either univariable or multivariable analysis (online supplemental table 1).

In the subgroup of 565 patients with stage IV M1c/M1d treated in any line of systemic therapy, 12 (12%)/103 patients with symptomatic brain metastases experienced

Table 1 Baseline characteristics

	Anti-PD1, any line	Anti-PD1, first line
Number of patients	819	557
Age median (IQR)	65 (55–73)	67 (56–74)
Sex		
Male	472 (58%)	327 (59%)
Female	346 (42%)	229 (41%)
WHO performance status		
0	454 (61%)	332 (64%)
1	256 (34%)	166 (32%)
2	36 (5%)	21 (4%)
3	2 (0%)	2 (0%)
Number of comorbidities		
0	279 (34%)	179 (32%)
1–2	398 (49%)	276 (50%)
≥3	137 (17%)	100 (18%)
Stage of disease		
Unresectable stage III	53 (7%)	41 (8%)
IV, M1a	77 (10%)	55 (10%)
IV, M1b	102 (13%)	90 (17%)
IV, M1c	360 (45%)	250 (46%)
IV, M1d	205 (26%)	109 (20%)
Symptomatic brain metastases	103 (13%)	56 (10%)
Number of metastatic sites		
0	87 (11%)	63 (12%)
1	251 (33%)	180 (35%)
2	222 (29%)	146 (28%)
3	143 (19%)	84 (16%)
4	50 (7%)	33 (6%)
5	12 (2%)	9 (2%)
6	1 (0%)	1 (0%)
LDH		
≤ULN	548 (68%)	369 (67%)
1–2 × ULN	210 (26%)	155 (28%)
>2 × ULN	50 (6%)	27 (5%)
ICI treatment		
Nivolumab	261 (32%)	178 (32%)
Pembrolizumab	558 (68%)	379 (68%)
Line of systemic therapy		
1	557 (68%)	
2	208 (25%)	
3	39 (5%)	
≥4	15 (2%)	

ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; PD1, programmed cell death 1; ULN, upper limit of normal (defined as 250 U/L).

severe irAEs compared with 38 (11%)/360 of patients without any brain metastases (RR 1.10; 95% CI 0.55 to 2.05; RR_{adj} 1.47; 95% CI 0.77 to 2.83). In the 359 first-line

treated patients with stage IV M1c/M1d, 11 (20%)/56 of patients with symptomatic brain metastases experienced severe irAEs, compared with 25 (10%)/250 patients without any brain metastases (RR 1.96; 95% CI 0.93 to 3.89; RR_{adj} 2.35; 95% CI 1.11 to 4.97).

Approximately 60% of patients with symptomatic brain metastases received steroids at baseline, compared with 22% in all patients. Unfortunately, data on baseline steroid use were missing in 35% of patients. We did not observe a significant difference in frequency of severe irAEs in patients with (15.7%) and without (12.9%) baseline steroids for patients treated in any line (RR 1.21; 95% CI 0.69 to 2.03). Nevertheless, when we repeated the multivariable analyses with additional adjustment for baseline steroid use, the correlation between disease severity and severe irAEs did not change relevantly in patients treated in any line of therapy (RR_{adj} for stage 0.49; 95% CI 0.28 to 0.84) and first-line treated patients only (RR_{adj} 0.46; 95% CI 0.24 to 0.90). Notably, there was no imbalance of baseline autoimmune disorders between patients with high stage (3.7%) compared with low-stage disease (1.8%; χ^2 p value 0.231).

DISCUSSION

In the largest prospective cohort thus far, using data from the nationwide DMTR, we aimed to identify patient-related and tumour-related factors associated with the occurrence of severe irAEs in patients with advanced melanoma treated with anti-PD1. We observed that patients with more advanced disease (stage IV M1c or higher) had a significantly decreased risk of severe irAEs compared with patients with lower-stage disease (stage IV M1b or lower). None of the other factors were associated with the occurrence of severe irAEs. When looking at first-line treated patients only, we observed comparable results, although the association for more advanced disease was not significant, probably due to lower number of patients.

Recently, the high toxicity rates in early (neo)adjuvant studies have led to the hypothesis that irAEs occur more frequently in patients with smaller tumour load.^{7–28} Although no data on tumour volumes are available in the DMTR, tumour load was previously reported to be larger in stage M1c or higher than in patients with a lower stage of disease,²⁹ pointing in the same direction. Moreover, the non-significant lower risk we observed in the small group of LDH $\geq 2 \times$ ULN patients supports this. Interestingly, also response rates to anti-PD1 are lower in patients with stage IV M1c melanoma compared with lower stages,³⁰ in patients with higher tumour load²⁹ and LDH $\geq 2 \times$ ULN.³¹ As we and others have recently shown a correlation between ICI response and toxicity,^{32–33} one may hypothesise that immunological responses in these patients are less strong, which might be due to the increased immunosuppressive tumour microenvironment in large volume disease.³⁴

It is unlikely that the observed association between stage and severe irAEs is explained by immortal time bias, as we

**Table 2** Determinants of severe immune-related adverse events in any line anti-PD1-treated patients using both univariable and multivariable Poisson regression

	Univariable analysis			Multivariable analysis		
	RR	95% CI	P value	RR _{adj}	95% CI _{adj}	P value
Age	1.01	0.99–1.02	0.491	1.00	0.99–1.02	0.676
Sex						
Male	ref			ref		
Female	1.18	0.81–1.71	0.389	1.18	0.81–1.73	0.397
WHO performance status						
0	ref			ref		
1	0.52	0.53–1.24	0.363	0.96	0.62–1.49	0.845
≥2	0.89	0.31–2.00	0.805	1.04	0.41–2.64	0.942
Number of comorbidities						
0	ref			ref		
1–2	1.27	0.83–1.98	0.277	1.16	0.73–1.86	0.529
≥3	1.27	0.72–2.07	0.397	1.21	0.65–2.28	0.539
Stage of disease						
Unresectable stage III/M1a/M1b	ref			ref		
M1c/M1d	0.57	0.39–0.85	0.046	0.63	0.41–0.94	0.026
Number of metastatic sites						
<3	ref			ref		
≥3	0.77	0.47–1.21	0.271	1.03	0.65–1.62	0.906
LDH						
≤ULN	ref			ref		
1–2 × ULN	0.95	0.61–1.44	0.812	1.12	0.72–1.74	0.623
>2 × ULN	0.43	0.10–1.14	0.148	0.65	0.20–2.13	0.475
Line of therapy	1.01	0.76–1.26	0.950	1.12	0.86–1.46	0.417

CI_{adj}, adjusted CI; LDH, lactate dehydrogenase; ; PD1, programmed cell death 1; RR, risk ratio; RR_{adj}, adjusted risk ratio; ULN, upper limit of normal (defined as 250 U/L); the multivariable analysis was additionally adjusted for follow-up time.

adjusted for follow-up time. Furthermore, the association persisted when we excluded patients who died within the first 3 months after treatment initiation, in which most toxicities occur.²³ Moreover, patients with symptomatic brain metastases—who have a very poor prognosis—had a similar or even increased irAE risk when compared with patients with stage IV M1c without brain metastases. Furthermore, treatment duration did not differ significantly between patients with and those without severe irAEs. However, this should be interpreted with caution as treatment duration is unknown in a considerable proportion of patients, presumably because these patients are still on treatment. This may have resulted in an underestimation of treatment duration, which is probably more pronounced in patients without irAEs. Together, this suggests that the lower risk in patients with high-stage disease was not due to decreased time at risk.

Several others have tried to identify determinants of ICI induced toxicity. For example, baseline body mass index, platelet to lymphocyte ratio, absolute lymphocyte count and absolute eosinophil count were reported to be correlated with irAEs resulting from anti-PD1

therapy.^{11 17 18} However, sample sizes in these studies were small ($n < 200$ at risk), resulting in wide confidence intervals. Most studies also report numerous other tested variables without significant predictive value.

As most autoimmune diseases display a female predominance,⁴ sex differences in irAEs have been hypothesised, but reports on the association of sex with irAEs are contradictory. Two cohort studies of <250 patients demonstrated an increased frequency of irAEs in females compared with males, although for frequency of grade ≥3 irAEs one of the studies showed no difference between both sexes.^{8 9} Contrastingly, in a retrospective analysis using insurance data of 4438 ICI-treated patients, Kehl *et al* reported no significant difference in risk of irAEs (RR_{adj} 1.11; 95% CI 0.91 to 1.34) between females and males.³⁵ Similarly, the frequency of severe irAEs was not higher in females in our cohort compared with males. With a median age of 65 years, and with just 65 females younger than 50 years, our real-world cohort encompasses mainly postmenopausal women. As differences between male and female immune responses alter with age, with a supposedly important role of sex hormones, the discrepancy between sex-differences

in autoimmune diseases compared with irAEs may be age-related. Besides, most severe irAEs (such as colitis) resemble autoimmune diseases with a sex distribution close to 50% (such as ulcerative colitis),³⁶ while rheumatological and thyroidal irAEs are often lower grade and therefore in general not included in our registry. Of note, reports on the association of sex with ICI efficacy are contradictory.^{6 30 37}

In conclusion, we demonstrated that anti-PD1-treated patients with more advanced disease have a lower risk of developing severe irAEs. No associations of sex or other patient-related and tumour-related factors with severe irAEs were found. As toxicity profiles are similar between tumour types, the results of this study are possibly applicable to other patients treated with anti-PD1 therapy.

Author affiliations

- ¹Department of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands
- ²University Medical Center Utrecht, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht, The Netherlands
- ³Department of Medical Oncology and Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- ⁴Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
- ⁵Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
- ⁶Department of Medical Oncology, Maastricht UMC+, Maastricht, The Netherlands
- ⁷Department of Medical Oncology, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, The Netherlands
- ⁸Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
- ⁹Oncology Center Isala, Isala Zwolle, Zwolle, The Netherlands
- ¹⁰Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands
- ¹¹Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
- ¹²Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
- ¹³Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands
- ¹⁴Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands
- ¹⁵Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
- ¹⁶Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands
- ¹⁷Department of Medical and Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- ¹⁸Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, Amsterdam, The Netherlands

Twitter John B A G Haanen @HaanenJohn

Contributors Study conception and design were done by RJV, AMM and KPMS. Acquisition of data was by CUB, AAMvdV, MJB-S, MJBA, FWPJvdB, AJMvdE, JWBdG, JJMvdH, GAPH, DP, RSvR, AJtT, GV, MCTvZ, MWJMW, JBAGH, EK and KPMS. Analysis and interpretation of data were performed by RJV, AMM, EK and KPMS. Writing, review and/or revision were done by RJV, AMM, CUB, AAMvdV, MJB-S, MJBA, FWPJvdB, AJMvdE, JWBdG, JJMvdH, GAPH, DP, RSvR, AJtT, GV, MCTvZ, MWJMW, JBAGH, EK and KPMS.

Funding The Netherlands Organisation for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836 002 002. This grant was awarded under the effectiveness research for high-cost medicine programme. From its foundation, the DMTR has been sponsored by BMS, Novartis, Roche Nederland BV, MSD and Pierre Fabre via the Dutch Institute for Clinical Auditing (DICA).

Competing interests CUB reports receiving commercial research grants from Novartis, Bristol-Myers Squibb, and NanoString; is a paid advisory board member for Bristol-Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca,

Pfizer, Lilly, GenMab and Pierre Fabre; and holds ownership interest in Uniti Cars, Neon Therapeutics and Forty Seven. AJMvdE reports receiving commercial research grants from Bristol-Myers Squibb; reports receiving speakers bureau honoraria from Bristol-Myers Squibb and Novartis; and is an unpaid consultant/advisory board member for Bristol-Myers Squibb, Novartis, MSD, Pierre Fabre and AMGEN. JWDG is a paid consultant for Bristol-Myers Squibb and MSD. GAH is an unpaid consultant/advisory board member for Bristol-Myers Squibb, MSD, Roche and Novartis. AAMvdV is a paid consultant for Bristol-Myers Squibb, MSD, Novartis, Roche, Pfizer, Eisai, Ipsen, Pierre Fabre, Sanofi and Bayer. JBAGH is a paid consultant for AIMM, Neon Therapeutics, Immunocore, Vaximm and Neogene Therapeutics, and reports receiving commercial research grants from Bristol-Myers Squibb, MSD, Novartis and Neon Therapeutics. EK is a paid advisory board member for Bristol-Myers Squibb, Novartis, Merck/MSD and Pierre Fabre, and reports receiving commercial research grants from Bristol-Myers Squibb. KPMS reports receiving speakers bureau honoraria from Novartis and Roche, and is an unpaid consultant/advisory board member for Novartis, Roche, MSD, Pierre Fabre and Bristol-Myers Squibb.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Rik J Verheijden <http://orcid.org/0000-0003-1966-1063>
 Christian U Blank <http://orcid.org/0000-0002-7945-5846>
 John B A G Haanen <http://orcid.org/0000-0001-5884-7704>

REFERENCES

- 1 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–64.
- 2 Larkin J, Chiarion-Sileni V, Gonzalez R, *et al*. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 2015;373:23–34.
- 3 Wang DY, Salem J-E, Cohen JV, *et al*. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. *JAMA Oncol* 2018;4:1721–8.
- 4 Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. *Front Neuroendocrinol* 2014;35:347–69.
- 5 van der Vliet M, Kuball J, Radstake TRD, *et al*. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? *Nat Rev Rheumatol* 2016;12:593–604.
- 6 Özdemir BC, Coukos G, Wagner AD. Immune-related adverse events of immune checkpoint inhibitors and the impact of sex—what we know and what we need to learn. *Ann Oncol* 2018;29:1067.
- 7 Sondak VK, McArthur GA. Adjuvant immunotherapy for cancer: the next step. *Lancet Oncol* 2015;16:478–80.
- 8 Duma N, Abdel-Ghani A, Yadav S, *et al*. Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal? *Oncologist* 2019;24:e1148–55.
- 9 Valpione S, Pasquali S, Campana LG, *et al*. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. *J Transl Med* 2018;16:94.
- 10 Kartolo A, Sattar J, Sahai V, *et al*. Predictors of immunotherapy-induced immune-related adverse events. *Curr Oncol* 2018;25:e403–10.
- 11 Heidelberger V, Goldwasser F, Kramkimel N, *et al*. Sarcopenic overweight is associated with early acute limiting toxicity of anti-



- PD1 checkpoint inhibitors in melanoma patients. *Invest New Drugs* 2017;35:436–41.
- 12 Daly LE, Power DG, O'Reilly Áine, *et al.* The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. *Br J Cancer* 2017;116:310–7.
 - 13 Sakata Y, Kawamura K, Ichikado K, *et al.* The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. *Lung Cancer* 2019;130:159–61.
 - 14 Dumenil C, Massiani M-A, Dumoulin J, *et al.* Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. *PLoS One* 2018;13:e0195945.
 - 15 Gowen MF, Giles KM, Simpson D, *et al.* Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. *J Transl Med* 2018;16:82.
 - 16 Damuzzo V, Solito S, Pinton L, *et al.* Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. *Oncoimmunology* 2016;5:e1249559.
 - 17 Diehl A, Yarchoan M, Hopkins A, *et al.* Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. *Oncotarget* 2017;8:114268–80.
 - 18 Pavan A, Calvetti L, Dal Maso A, *et al.* Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. *Oncologist* 2019;24:1128–36.
 - 19 Owen DH, Wei L, Bertino EM, *et al.* Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. *Clin Lung Cancer* 2018;19:e893–900.
 - 20 Dubin K, Callahan MK, Ren B, *et al.* Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. *Nat Commun* 2016;7:10391.
 - 21 Chaput N, Lepage P, Coutzac C, *et al.* Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Ann Oncol* 2017;28:1368–79.
 - 22 Jochems A, Schouwenburg MG, Leeneman B, *et al.* Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. *Eur J Cancer* 2017;72:156–65.
 - 23 Weber JS, Hodi FS, Wolchok JD, *et al.* Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. *J Clin Oncol* 2017;35:785–92.
 - 24 McNutt L-A, Wu C, Xue X, *et al.* Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am J Epidemiol* 2003;157:940–3.
 - 25 Knol MJ, Duijnhoven RG, Grobbee DE, *et al.* Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials. *PLoS One* 2011;6:e21248.
 - 26 Buuren Svan, Groothuis-Oudshoorn K. mice : Multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45.
 - 27 von Hippel PT. 8. How to impute interactions, squares, and other transformed variables. *Sociol Methodol* 2009;39:265–91.
 - 28 Blank CU, Rozeman EA, Fanchi LF, *et al.* Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med* 2018;24:1655–61.
 - 29 Joseph RW, Elassaiss-Schaap J, Kefford R, *et al.* Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. *Clin Cancer Res* 2018;24:4960–7.
 - 30 Weide B, Martens A, Hassel JC, *et al.* Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. *Clin Cancer Res* 2016;22:5487–96.
 - 31 Schouwenburg MG, Suijkerbuijk KPM, Koornstra RHT, *et al.* Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? *Cancers* 2019;11:1940.
 - 32 Verheijden RJ, May AM, Blank CU, *et al.* Association of anti-TNF with decreased survival in steroid refractory ipilimumab and Anti-PD1-Treated patients in the Dutch melanoma treatment registry. *Clin Cancer Res* 2020;26:2268–74.
 - 33 Eggermont AMM, Kicinski M, Blank CU, *et al.* Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. *JAMA Oncol* 2020;6:519.
 - 34 Warner AB, Postow MA. Bigger is not always better: tumor size and prognosis in advanced melanoma. *Clin Cancer Res* 2018;24:4915–7.
 - 35 Kehl KL, Yang S, Awad MM, *et al.* Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. *Cancer Immunol Immunother* 2019;68:917–26.
 - 36 Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol* 2001;2:777–80.
 - 37 Carrera C, Potrony M, Puig S. Sex as a predictor of response to cancer immunotherapy. *Lancet Oncol* 2018;19:e375.